WO2008140051A1 - 非麦角系の選択的ｄ２受容体アゴニストを有効成分として含有する後眼部疾患の予防又は治療剤 - Google Patents

非麦角系の選択的ｄ２受容体アゴニストを有効成分として含有する後眼部疾患の予防又は治療剤 Download PDF

Info

Publication number
WO2008140051A1
WO2008140051A1 PCT/JP2008/058655 JP2008058655W WO2008140051A1 WO 2008140051 A1 WO2008140051 A1 WO 2008140051A1 JP 2008058655 W JP2008058655 W JP 2008058655W WO 2008140051 A1 WO2008140051 A1 WO 2008140051A1
Authority
WO
WIPO (PCT)
Prior art keywords
posterior ocular
therapeutic agent
prophylactic
ocular disease
receptor agonist
Prior art date
Application number
PCT/JP2008/058655
Other languages
English (en)
French (fr)
Inventor
Kazuyoshi Okamoto
Keiichi Shibagaki
Original Assignee
Santen Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co., Ltd. filed Critical Santen Pharmaceutical Co., Ltd.
Priority to CN200880015685A priority Critical patent/CN101678006A/zh
Priority to ES08752538T priority patent/ES2374336T3/es
Priority to EP08752538A priority patent/EP2156833B1/en
Priority to AT08752538T priority patent/ATE535243T1/de
Priority to RU2009145939/15A priority patent/RU2470635C2/ru
Priority to CA002686394A priority patent/CA2686394A1/en
Priority to US12/451,282 priority patent/US20100130569A1/en
Publication of WO2008140051A1 publication Critical patent/WO2008140051A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

　本発明は後眼部疾患の新たな予防又は治療剤を提供する。非麦角系の選択的Ｄ２受容体アゴニストであるプラミペキソール又はその塩は、脈絡膜、網膜といった後眼部組織において、優れた血管新生阻害作用、視細胞障害抑制作用及び血管透過性亢進抑制作用を発揮するので、加齢黄斑変性、糖尿病網膜症又は糖尿病黄斑浮腫などの後眼部疾患の予防又は治療剤として有用である。
PCT/JP2008/058655 2007-05-11 2008-05-09 非麦角系の選択的ｄ２受容体アゴニストを有効成分として含有する後眼部疾患の予防又は治療剤 WO2008140051A1 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN200880015685A CN101678006A (zh) 2007-05-11 2008-05-09 含有非麦角类的选择性d2受体激动剂作为有效成分的后眼部疾病的预防或治疗剂
ES08752538T ES2374336T3 (es) 2007-05-11 2008-05-09 Agente profiláctico o terapéutico para una enfermedad ocular posterior que comprende un agonista selectivo no ergótico del receptor d2 como principio activo.
EP08752538A EP2156833B1 (en) 2007-05-11 2008-05-09 Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
AT08752538T ATE535243T1 (de) 2007-05-11 2008-05-09 Prophylaktisches oder therapeutisches mittel für posteriore augenerkrankung mit selektivem nicht- ergot-d2-rezeptoragonist als wirkstoff
RU2009145939/15A RU2470635C2 (ru) 2007-05-11 2008-05-09 Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
CA002686394A CA2686394A1 (en) 2007-05-11 2008-05-09 Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
US12/451,282 US20100130569A1 (en) 2007-05-11 2008-05-09 Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007126232 2007-05-11
JP2007-126232 2007-05-11

Publications (1)

Publication Number Publication Date
WO2008140051A1 true WO2008140051A1 (ja) 2008-11-20

Family

ID=40002247

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2008/058657 WO2008140052A1 (ja) 2007-05-11 2008-05-09 ロピニロール又はその塩を有効成分として含有する後眼部疾患の予防又は治療剤
PCT/JP2008/058655 WO2008140051A1 (ja) 2007-05-11 2008-05-09 非麦角系の選択的ｄ２受容体アゴニストを有効成分として含有する後眼部疾患の予防又は治療剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/058657 WO2008140052A1 (ja) 2007-05-11 2008-05-09 ロピニロール又はその塩を有効成分として含有する後眼部疾患の予防又は治療剤

Country Status (10)

Country Link
US (1) US20100130569A1 (ja)
EP (1) EP2156833B1 (ja)
JP (2) JP2008308489A (ja)
KR (1) KR20100016270A (ja)
CN (1) CN101678006A (ja)
AT (1) ATE535243T1 (ja)
CA (1) CA2686394A1 (ja)
ES (1) ES2374336T3 (ja)
RU (1) RU2470635C2 (ja)
WO (2) WO2008140052A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518233A (ja) * 2011-06-28 2014-07-28 バイエル・ヘルスケア・エルエルシー レゴラフェニブを含有する眼科用局所医薬組成物
RU2598348C1 (ru) * 2015-09-23 2016-09-20 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации Способ лечения экспериментальной ретинопатии недоношенных
JP2016531940A (ja) * 2013-09-30 2016-10-13 オリオン コーポレーション 嘔吐を誘導するための獣医学的方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ATE537826T1 (de) 2006-05-16 2012-01-15 Knopp Neurosciences Inc Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
EP2137171A4 (en) 2007-03-14 2010-05-19 Knopp Neurosciences Inc SYNTHESIS OF BENZOTHIAZOLE DIAMINES SUBSTITUTED AND PURIFIED FROM THE CHIRAL PERSPECTIVE
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
RS61539B1 (sr) 2013-07-12 2021-04-29 Knopp Biosciences Llc Lečenje povišenih nivoa eozinofila i/ili bazofila
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
CA2921381A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
EP2870965A1 (en) * 2013-11-06 2015-05-13 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical formulations of pramipexole
PL232974B1 (pl) 2015-12-09 2019-08-30 Ofta Spolka Z Ograniczona Odpowiedzialnoscia Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001136A1 (de) 1989-07-18 1991-02-07 Boehringer Ingelheim Kg Tetrahydrobenzthiazolderivate zur behandlung von augenkrankheiten
JPH0572907B2 (ja) 1984-12-22 1993-10-13 Thomae Gmbh Dr K
JP2004323486A (ja) * 2003-04-30 2004-11-18 National Institute Of Advanced Industrial & Technology 網膜及び／又はブドウ膜疾患の予防乃至治療用点眼薬
JP2006176499A (ja) * 2004-11-25 2006-07-06 Nippon Seibutsu Seizai:Kk 眼疾患治療剤
WO2007121188A2 (en) * 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386098A (en) * 1981-11-03 1983-05-31 Merck & Co., Inc. 6-Hydroxy-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure
US4452808A (en) * 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
DK1246623T3 (da) * 1999-12-02 2006-11-13 Osi Pharm Inc Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf
GB0106661D0 (en) * 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
RS35404A (en) * 2001-11-09 2006-10-27 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
UY28326A1 (es) * 2003-05-22 2004-06-30 Osmotica Argentina S A Dispositivo de ruptura de liberacion controlada con un pasaje preformado
JP2009504748A (ja) * 2005-08-15 2009-02-05 ユニバーシティ オブ バージニア パテント ファウンデーション Ｒ（＋）プラミペキソールを用いた神経回復

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0572907B2 (ja) 1984-12-22 1993-10-13 Thomae Gmbh Dr K
WO1991001136A1 (de) 1989-07-18 1991-02-07 Boehringer Ingelheim Kg Tetrahydrobenzthiazolderivate zur behandlung von augenkrankheiten
JP2004323486A (ja) * 2003-04-30 2004-11-18 National Institute Of Advanced Industrial & Technology 網膜及び／又はブドウ膜疾患の予防乃至治療用点眼薬
JP2006176499A (ja) * 2004-11-25 2006-07-06 Nippon Seibutsu Seizai:Kk 眼疾患治療剤
WO2007121188A2 (en) * 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Macular Disease Textbook and Atlas", IGAKU-SHOIN LTD., pages: 43 - 45
"New Illustrated Handbook of Clinical Ophthalmology", vol. 5, 2000, MEDICAL VIEW, article "Vitreoretinal Diseases", pages: 184 - 189
CANCER RES., vol. 64, 2004, pages 5551 - 5555
CLINICAL CANCER RESEARCH, vol. 10, 2004, pages 4349 - 4356
DANZEISEN R. ET AL.: "Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-L-propylamino-benzathiazole dihydrochloride]", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 316, no. 1, 2006, pages 189 - 199, XP008125303 *
INVEST. OPHTHALMOL. VIS. SCI., vol. 46, 2005, pages 979 - 987
JOURNAL OF JAPANESE OPHTHALMOLOGICAL SOCIETY, vol. 103, 1999, pages 923 - 947
JOURNAL OF JAPANESE OPHTHALMOLOGICAL SOCIETY, vol. 93, 1989, pages 978 - 985
KONO Y. ETAL.: "Parkinson's Disease Chiryoyaku Ensan Pramipexole (BI.Sifrol Tablets) no Yakuri Sayo to Rinsho Seiseki", FOLIA PHARMACOLOGICA JAPONICA, vol. 123, no. 6, 1 June 2004 (2004-06-01), pages 429 - 440, XP008125302 *
MIZUNO Y. ET AL.: "Parkinson's Disease ni Taisuru SND 919 (pramipexole) no Choki Toyo Shiken", NEUROLOGICAL THERAPEUTICS, vol. 20, no. 4, 25 July 2003 (2003-07-25), pages 465 - 477, XP008141300 *
NATURE MED., vol. 7, 2001, pages 569 - 574
NIPPON BOEHRINGER INGELHEIM CO., LTD.: "Tenpu Bunsho (BI.Sifrol Tablets o.125mg BI.Sifrol Tablets 0.5mg)", November 2006 (2006-11-01), pages 1 - 4, XP008118265 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518233A (ja) * 2011-06-28 2014-07-28 バイエル・ヘルスケア・エルエルシー レゴラフェニブを含有する眼科用局所医薬組成物
JP2016531940A (ja) * 2013-09-30 2016-10-13 オリオン コーポレーション 嘔吐を誘導するための獣医学的方法
RU2598348C1 (ru) * 2015-09-23 2016-09-20 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации Способ лечения экспериментальной ретинопатии недоношенных

Also Published As

Publication number Publication date
RU2009145939A (ru) 2011-06-20
JP2008308488A (ja) 2008-12-25
RU2470635C2 (ru) 2012-12-27
WO2008140052A1 (ja) 2008-11-20
CA2686394A1 (en) 2008-11-20
KR20100016270A (ko) 2010-02-12
EP2156833B1 (en) 2011-11-30
ATE535243T1 (de) 2011-12-15
JP2008308489A (ja) 2008-12-25
US20100130569A1 (en) 2010-05-27
CN101678006A (zh) 2010-03-24
ES2374336T3 (es) 2012-02-15
EP2156833A1 (en) 2010-02-24
EP2156833A4 (en) 2010-11-24

Similar Documents

Publication Publication Date Title
WO2008140051A1 (ja) 非麦角系の選択的ｄ２受容体アゴニストを有効成分として含有する後眼部疾患の予防又は治療剤
EP2427174A4 (en) HEMMER OF THE MTOR SIGNAL PATH FOR THE TREATMENT OF EYE TROUBLE
WO2008111497A1 (ja) トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
WO2007044668A3 (en) Compstatin and analogs thereof for eye disorders
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2008019417A3 (en) Treatment of ocular diseases
WO2013030679A3 (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
DK1904056T3 (da) Anvendelse af et macrolid til at gendanne korneal fölelse
WO2004043480A3 (en) Intraocular administration of cyclosporin a for the treatment of macular degeneration, retinopathy or retinitis pigmentosa
WO2007011880A3 (en) Enhanced ocular neuroprotection/neurostimulation
WO2010093945A3 (en) Uveoscleral drug delivery implant and methods for implanting the same
WO2007075720A3 (en) Topical mecamylamine formulations for ocular administration and uses thereof
WO2006062731A8 (en) Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
NZ588938A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
WO2007043052A3 (en) Device, system and method for dual-path ophthalmic device
WO2010059214A3 (en) Biocompatible biodegradable intraocular implant system
WO2006036715A3 (en) Implant and pressure sensor for glaucoma treatment
WO2007070866A3 (en) Control of intraocular pressure using alk5 modulation agents
MX2007007614A (es) Agente preventivo o terapeutico para glaucoma.
WO2006039252A3 (en) Compositions and methods for treating ophthalmic diseases
CL2007002386A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.
WO2003082081A3 (en) Use of rom production and release inhibitors to treat and prevent intraocular damage
MY176525A (en) Therapeutic agent for ocular disease or prophylactic agent for ocular disease
WO2005102303A3 (en) Antiprostaglandins for the treatment of ocular pathologies
WO2009116076A3 (en) Ophthalmic preparation containing a pyridinol derivative

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880015685.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08752538

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2686394

Country of ref document: CA

Ref document number: 12451282

Country of ref document: US

ENP Entry into the national phase

Ref document number: 20097023170

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008752538

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009145939

Country of ref document: RU

NENP Non-entry into the national phase

Ref country code: JP